title: Considering the affordability of ticagrelor when used according to NICE guidance.
authors.affiliation: NHS Airedale, Bradford and Leeds, Douglas Mill, Bradford, UK. greg.fell@bradford.gov.uk.
authors.forename: G
authors.initials: G
authors.lastname: Fell
authors.forename: B
authors.initials: B
authors.lastname: Reynolds
authors.forename: S
authors.initials: S
authors.lastname: Lindsay
authors.forename: T
authors.initials: T
authors.lastname: Keegan
authors.forename: D
authors.initials: D
authors.lastname: Lee
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D000789:Angina, Unstable / Q000188:drug therapy / Q000191:economics*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004739:England; D019983:Guideline Adherence; D006801:Humans; D008017:Life Expectancy; D018803:Models, Economic; D009203:Myocardial Infarction / Q000188:drug therapy / Q000191:economics*; D017410:Practice Guidelines as Topic; D058921:Purinergic P2Y Receptor Antagonists / Q000191:economics* / Q000627:therapeutic use; D000077486:Ticagrelor
chemical_list: D058921:Purinergic P2Y Receptor Antagonists; D000077486:Ticagrelor; D000241:Adenosine